6Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol, 1995, 22: 1217-1219.
7Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum, 1980, 23: 137-145.
8Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hcmatopoiesis-supportive function and other potentials. Haematologica, 2006, 91: 1017-1026.
9Sun LY, Zhang HY, Feng XB, et al. Abnormality of bone marrow-derived stem cell in patient with systemic lupus erythematosus. Lupus, 2007, 16: 121-128.
10Lakos G, Takagawa S, Chen S J, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol, 2004, 165: 203-217.
4Picken MM. The changing concepts of amyloid. Arch Pathol LabMed, 2001,125 :38-43.
5Merini G,Bellotti V. Molecular mechanismas of amyloidosis. NEngl J Med, 2003,349, (6) ; 584-596.
6Comenzo RL,Vosburgh E,Falk RH,et al. Dose-intensive mel-phalan with blood stem-cell support for the treatment of AL amy-loidosis :survival and responses in 25 patients. Blood, 1998,91:3662-3670.
7Wcchalekar AD,Goodman HJ,Lachmann HJ,et al. Safety andefficacy of risk-adapted cyclophos-phamide, thalidiomde, anddexamethasone in systemic AL amyloidosis. Blood, 2007,109 :457-464.
8Sanchorawala V,Skinner M,Quillen K,et al. Long-term outcomeof patients with AL amyloidosis treated with high-dose melphalanand stem-cell transplantation. Blood,2007,110:3561-3563.
